MAPT and supranuclear palsy, progressive, 1: In the last years, few clinical trials targeting mitochondria dysfunction, tau aggregation or MT stability have been performed or are ongoing.16 Besides other promising drugs, davunetide, which promotes MT stability, was effective as neuroprotective agent in a mouse model of tauopathy17 but it failed in a phase 2/3 clinical trial on patients with PSP,18 while TPI‐287, another MT stabilizer molecule, has recently entered a phase 1 clinical trial (Trial registration: ClinicalTrials.gov identifier NCT02133846).